PGS

(Pre-implantation Genetic Screening)

GenoBro is an NGS-based PGS (pre-implantation screening) test that selects genetically normal embryos. It has a much higher sensitivity and suspend time than conventional methods (FISH, aCGH) and can shorten inspection time.

Increased implantation and pregnancy success rates and elimination of embryos with chromosomal abnormalities can reduce abortion rate.

WHAT is

PSG?

Pre-implantation genetic screening (PGS) for aneuploidy is a powerful genetic test that may be performed on embryos during IVF treatment to screen for numerical chromosomal abnormalities. PGS is performed on a small embryo biopsy prior to transfer and identifies which embryos are chromosomally normal. Chromosomally normal embryos are the most likely to develop to term and to be born as a healthy baby. PGS testing helps IVF physicians and patients decide which embryos to transfer.

WHO need

PGS?

  • Women over 35 years of age who try In-vitro fertilization

  • Women with several cycles of IVF that have not achieved  pregnancy

  • Women who have family history of structural abnormalities of certain chromosomes or have experience of pregnancy of such a child

  • If a doctor recommended or women herself want

PGS

PRINCIPLE

After the in vitro fertilization, the embryo is harvested from 3 to 5 days after the amplification of the DNA, and then analyzed by using the next generation genome sequencing technology, which is the latest analysis technology, to analyze the chromosome abnormality more quickly and accurately. Because of this principle, the Embryos with normal chromosomes can be screened.

PGS

PROCESS

  • Collecting a part of cells collecting

  • DNA Separation and Amplification 

  • Library production 

  • Sequencing

  • Precise analysis

  • Check for chromosomal abnormality

810 Gwanggyo Central Biz Tower, Suwon-si, Gyeonggi-do, Republic of Korea   e-mail : info@genomecare.net

©2020 by THERAGEN GENOMECARE.

All rights reserved.